2022
Investigating Health Disparities Associated With Multisystem Inflammatory Syndrome in Children After SARS-CoV-2 Infection
Zambrano LD, Ly KN, Link-Gelles R, Newhams MM, Akande M, Wu MJ, Feldstein LR, Tarquinio KM, Sahni LC, Riggs BJ, Singh AR, Fitzgerald JC, Schuster JE, Giuliano JS, Englund JA, Hume JR, Hall MW, Osborne CM, Doymaz S, Rowan CM, Babbitt CJ, Clouser KN, Horwitz SM, Chou J, Patel MM, Hobbs C, Randolph AG, Campbell AP, Investigators F. Investigating Health Disparities Associated With Multisystem Inflammatory Syndrome in Children After SARS-CoV-2 Infection. The Pediatric Infectious Disease Journal 2022, 41: 891-898. PMID: 36102740, PMCID: PMC9555608, DOI: 10.1097/inf.0000000000003689.Peer-Reviewed Original ResearchConceptsMIS-C casesNon-Hispanic black childrenInflammatory syndromeRisk factorsMedical conditionsMixed-effects multivariable logistic regressionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2MIS-C patientsMultisystem inflammatory syndromeUnderlying medical conditionsMultivariable logistic regressionSyndrome coronavirus 2Case-control studyNon-Hispanic blacksBlack childrenMultivariable analysisPediatric hospitalCoronavirus 2Insurance statusIndependent factorsSimilar sexSocial Vulnerability Index
2021
Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents
Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, Maddux AB, Hall MW, Riggs BJ, Singh AR, Giuliano JS, Hobbs CV, Loftis LL, McLaughlin GE, Schwartz SP, Schuster JE, Babbitt CJ, Halasa NB, Gertz SJ, Doymaz S, Hume JR, Bradford TT, Irby K, Carroll CL, McGuire JK, Tarquinio KM, Rowan CM, Mack EH, Cvijanovich NZ, Fitzgerald JC, Spinella PC, Staat MA, Clouser KN, Soma VL, Dapul H, Maamari M, Bowens C, Havlin KM, Mourani PM, Heidemann SM, Horwitz SM, Feldstein LR, Tenforde MW, Newburger JW, Mandl KD, Randolph AG, Investigators O. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine 2021, 40: 101112. PMID: 34485878, PMCID: PMC8405351, DOI: 10.1016/j.eclinm.2021.101112.Peer-Reviewed Original ResearchSARS-CoV-2 PCRCluster 1 patientsInflammatory syndromeClinical featuresPositive SARS-CoV-2 PCRAcute COVID-19 pneumoniaCOVID-19 pulmonary diseaseCOVID-19-related illnessChest radiograph infiltratesHigher inflammatory biomarkersPositive PCR testingAcute COVID-19Multisystem inflammatory syndromeCOVID-19 pneumoniaDiagnosis of MISCluster 3 patientsCluster 2 patientsClusters of patientsPre-existing conditionsPulmonary infiltratesInflammatory biomarkersMucocutaneous involvementPulmonary diseaseRadiographic findingsMean ageMultisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, Loftis LL, Tarquinio KM, Singh AR, Heidemann SM, Soma VL, Riggs BJ, Fitzgerald JC, Kong M, Doymaz S, Giuliano JS, Keenaghan MA, Hume JR, Hobbs CV, Schuster JE, Clouser KN, Hall MW, Smith LS, Horwitz SM, Schwartz SP, Irby K, Bradford TT, Maddux AB, Babbitt CJ, Rowan CM, McLaughlin GE, Yager PH, Maamari M, Mack EH, Carroll CL, Montgomery VL, Halasa NB, Cvijanovich NZ, Coates BM, Rose CE, Newburger JW, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal Of Medicine 2021, 385: 23-34. PMID: 34133855, PMCID: PMC8220972, DOI: 10.1056/nejmoa2102605.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesCombined Modality TherapyCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleGlucocorticoidsHospitalizationHumansImmunoglobulins, IntravenousImmunomodulationInfantLogistic ModelsMalePropensity ScorePublic Health SurveillanceShockSystemic Inflammatory Response SyndromeTreatment OutcomeVentricular Dysfunction, LeftYoung AdultConceptsIntravenous immune globulinMultisystem inflammatory syndromeCardiovascular dysfunctionDay 2Immunomodulatory therapyInflammatory syndromePrimary outcomeInitial treatmentLower riskRisk of feverReal-world effectivenessYears of agePropensity-score matchingImmunomodulatory medicationsVasopressor useVentricular dysfunctionAdjunctive therapyComposite outcomeImmune globulinSecondary outcomesAdjunctive treatmentRecurrent feverInverse probability weightingDay 1GlucocorticoidsIncidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2
Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, Randolph AG, Newhams M, Thomas D, Magleby R, Hsu K, Burns M, Dufort E, Maxted A, Pietrowski M, Longenberger A, Bidol S, Henderson J, Sosa L, Edmundson A, Tobin-D’Angelo M, Edison L, Heidemann S, Singh AR, Giuliano JS, Kleinman LC, Tarquinio KM, Walsh RF, Fitzgerald JC, Clouser KN, Gertz SJ, Carroll RW, Carroll CL, Hoots BE, Reed C, Dahlgren FS, Oster ME, Pierce TJ, Curns AT, Langley GE, Campbell AP, Balachandran N, Murray T, Burkholder C, Brancard T, Lifshitz J, Leach D, Charpie I, Tice C, Coffin S, Perella D, Jones K, Marohn K, Yager P, Fernandes N, Flori H, Koncicki M, Walker K, Di Pentima M, Li S, Horwitz S, Gaur S, Coffey D, Harwayne-Gidansky I, Hymes S, Thomas N, Ackerman K, Cholette J. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Network Open 2021, 4: e2116420. PMID: 34110391, PMCID: PMC8193431, DOI: 10.1001/jamanetworkopen.2021.16420.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionMultisystem inflammatory syndromeRace/ethnicityInflammatory syndromeCohort studyPacific Islander personsAge groupsCurrent SARS-CoV-2 infectionIncidence of MISPopulation-based incidenceWhite personsPopulation-based estimatesEnhanced surveillance dataSARS-CoV-2Rare complicationCOVID-19 casesLatino personsNational surveillanceMAIN OUTCOMEInfectionDisease controlIncidenceSurveillance dataCOVID-19Further studiesNeurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, Walker TC, Singh AR, Dapul H, Hobbs CV, McLaughlin GE, Son MBF, Maddux AB, Clouser KN, Rowan CM, McGuire JK, Fitzgerald JC, Gertz SJ, Shein SL, Munoz AC, Thomas NJ, Irby K, Levy ER, Staat MA, Tenforde MW, Feldstein LR, Halasa NB, Giuliano JS, Hall MW, Kong M, Carroll CL, Schuster JE, Doymaz S, Loftis LL, Tarquinio KM, Babbitt CJ, Nofziger RA, Kleinman LC, Keenaghan MA, Cvijanovich NZ, Spinella PC, Hume JR, Wellnitz K, Mack EH, Michelson KN, Flori HR, Patel MM, Randolph AG, Last Name* F, Gaspers M, Typpo K, Sanders R, Schwarz A, Harvey H, Zinter M, Mourani P, Coates B, Bhoojhawon G, Havlin K, Montgomery V, Sullivan J, Bradford T, Bembea M, Lipton S, Graciano A, Chen S, Kucukak S, Newburger J, Carroll R, Fernandes N, Yager P, Marohn K, Heidemann S, Cullimore M, McCulloh R, Horwitz S, Li S, Walsh R, Ratner A, Soma V, Gillen J, Zackai S, Ackerman K, Cholette J, Harwayne-Gidansky I, Hymes S, Overby P, Schwartz S, Lansell A, Koncicki M, Carcillo J, Fink E, Kimura D, Bowens C, Crandall H, Smith L, Cengiz P. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurology 2021, 78: 536-547. PMID: 33666649, PMCID: PMC7936352, DOI: 10.1001/jamaneurol.2021.0504.Peer-Reviewed Original ResearchConceptsMultisystem inflammatory syndromeNeurologic involvementInflammatory syndromeLife-threatening conditionHospital dischargeTransient symptomsNeurologic conditionsPositive severe acute respiratory syndrome coronavirus 2 test resultCOVID-19Severe acute respiratory syndrome coronavirus 2Life-threatening neurologic conditionAcute respiratory syndrome coronavirus 2Long-term neurodevelopmental outcomesRespiratory syndrome coronavirus 2Fatal neurologic conditionFulminant cerebral edemaLife-threatening involvementNew neurologic deficitsAcute neurologic signsSyndrome coronavirus 2Coronavirus disease 2019Public health registriesFibrinogen equivalent unitsAdult patientsCerebral edemaCharacteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA 2021, 325: 1074-1087. PMID: 33625505, PMCID: PMC7905703, DOI: 10.1001/jama.2021.2091.Peer-Reviewed Original ResearchConceptsMultisystem inflammatory syndromeOrgan system involvementInflammatory syndromeCase seriesSystem involvementCardiorespiratory involvementCOVID-19Positive severe acute respiratory syndrome coronavirus 2Higher C-reactive protein levelsPositive RT-PCR test resultsSevere acute respiratory syndrome coronavirus 2Severe acute COVID-19Acute respiratory syndrome coronavirus 2C-reactive protein levelsSevere coronavirus disease 2019Left ventricular systolic functionRT-PCR test resultsRespiratory syndrome coronavirus 2Organ system complicationsAcute COVID-19Coronary artery aneurysmsVentricular systolic functionLow platelet countAntibody test resultsIntensive care unit
2020
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS, Gupta A, Parker RM, Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New England Journal Of Medicine 2020, 383: 334-346. PMID: 32598831, PMCID: PMC7346765, DOI: 10.1056/nejmoa2021680.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBetacoronavirusCenters for Disease Control and Prevention, U.S.ChildCoronavirus InfectionsCOVID-19Critical CareFemaleGlucocorticoidsHumansImmunoglobulins, IntravenousImmunomodulationInflammationLength of StayMaleMucocutaneous Lymph Node SyndromePandemicsPneumonia, ViralProspective StudiesRespiration, ArtificialRetrospective StudiesSARS-CoV-2Systemic Inflammatory Response SyndromeUnited StatesConceptsMultisystem inflammatory syndromeInflammatory syndromeSARS-CoV-2Antibody testingSevere acute respiratory syndrome coronavirus 2Kawasaki disease-like featuresAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Coronary artery aneurysmsIntravenous immune globulinMultisystem organ involvementEvidence of infectionOrgan system involvementSyndrome coronavirus 2Reverse transcriptase-polymerase chain reactionCoronavirus disease 2019Life-threatening illnessPediatric health centersPublic health implicationsImmunomodulating therapiesVasoactive supportImmune globulinMedian durationMost patientsOrgan involvement